Septerna, Inc.

Septerna is a U.S.-based biotechnology company focused on discovering and developing small-molecule medicines for diseases driven by G protein-coupled receptors (GPCRs). The company operates from South San Francisco, California and advances its programs through internal research, preclinical development, and collaboration arrangements with larger pharmaceutical partners.

−145,1 %

−106,4 %

+4 174,5 %

4.73

4.73

— Septerna, Inc.
%
Drug discovery platform0% Internal platform used to identify and optimize small-molecule GPCR drug candidates.
Preclinical product candidates0% Company-owned therapeutic programs advancing through discovery, IND-enabling work, and clinical preparation.
Research collaboration services100% Fee-based research services performed for pharmaceutical partners under collaboration agreements.
Milestone and royalty rights0% Potential future payments tied to development, regulatory, commercial, and sales outcomes.

Septerna’s direct customers today are pharmaceutical collaborators that fund research services and may support future...

  • Pharmaceutical collaboration partnersprimary

    Buy research services and provide funding, milestones, and future commercialization support for partnered programs.

  • Future commercial healthcare marketprimary

    Patients, physicians, and payors that would use or reimburse approved therapies from Septerna's pipeline.

  • Research and development collaboratorssecondary

    External partners that may access Septerna's discovery capabilities, data, or program-specific expertise.

Septerna is headquartered in South San Francisco, California and operates as a U.S.-based biotechnology company...

  • •Headquartered in South San Francisco, California
  • •Incorporated in Delaware and operated as a U.S. biotech company
  • •Current collaboration revenue is generated from partner research work
  • •Future royalties would be country-by-country on global product sales
  • •Third-party manufacturing and testing can involve non-U.S. supply chains

Septerna’s strategy is to build a differentiated GPCR drug discovery engine and convert that platform into partnered...

01
Advance core GPCR programsmedium-term

Clinical and preclinical progress is the main driver of long-term value creation.

02
Leverage collaborations for funding and validationshort-term

Partner agreements provide non-dilutive support and external validation of the platform.

03
Protect and expand intellectual propertylong-term

Patent and exclusivity protection are essential for future commercialization and royalty value.

Septerna faces the typical risks of an early-stage biotech company: clinical failure, regulatory delays, and dependence...

critical

Failure of product candidates in development

The company has no approved products, so pipeline setbacks would directly reduce future value.

Scope
PTH1R program, SEP-631, other GPCR candidates
Materiality
high
high

Reliance on third-party manufacturers and research providers

Septerna depends on external CROs, CMOs, and suppliers for development and testing.

Scope
Manufacturing, formulation, preclinical and clinical support
Materiality
high
high

Collaboration concentration

A meaningful share of current revenue comes from a small number of partners.

Scope
Novo collaboration agreement, Vertex research service agreement
Materiality
high
high

Regulatory and reimbursement uncertainty

Commercial success depends on obtaining approvals and later payer acceptance.

Scope
Future marketed GPCR therapies
Materiality
high
medium

Geopolitical and trade restrictions

Restrictions involving China or cross-border biotech supply chains could hinder development.

Scope
Third-party service providers and materials
Materiality
medium
Revenue recognition for collaboration services
Can create uneven quarterly revenue and earnings
Milestone and upfront payment accounting
Affects revenue timing and comparability across periods
Equity-based compensation
Impacts operating expenses and dilution
R&D capitalization and expense recognition
Drives reported losses and affects comparability

Natera, Inc.

NTRA · Services-Medical Laboratories

Xencor Inc

XNCR · Pharmaceutical Preparations

Kymera Therapeutics, Inc.

KYMR · Biological Products, (No Diagnostic Substances)

Aptera Motors Corp

SEV · Motor Vehicles & Passenger Car Bodies

CERO THERAPEUTICS HOLDINGS, INC.

CERO · Biological Products, (No Diagnostic Substances)

FILANA THERAPEUTICS, INC.

FLNA · Pharmaceutical Preparations

: 29/04/2026